Shots:

• Abbott’s Tendyne TMVI system received CE Mark to treat MR in patients requiring a heart valve replacement and is a safe and effective solution for patients who are not candidates for open-heart surgery or transcatheter mitral valve repair
• The approval in the EU allows HCPs to completely treat MR and expands Abbott’s portfolio of innovative minimally invasive mitral valve solutions
• Abbott’s Tendyne valve is a first-of-its-kind therapy to replace the mitral valve- without open surgery and when a transcatheter mitral repair is not possible. Tendyne valve provides relief from HF symptoms and improves QoL in high-surgical-risk patients

Click here to­ read full press release/ article |

Ref: Abbott | Image: Abbott